バージニアにおける急性骨髄性白血病の臨床試験
バージニア内の拠点で、急性骨髄性白血病に関する24件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
- NEXT Oncology Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07723703Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fairfax Hospital, Falls Church
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Virginia Commonwealth University - Massey Cancer Center, Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fairfax Hospital, Falls Church
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fairfax Hospital, Falls Church
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
- Virginia Commonwealth University, Richmond
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07710534A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Virginia Cancer Center, Charlottesville
- Inova Fairfax Hospital, Falls Church
- Children's Hospital of The King's Daughters, Norfolk
- 他3件
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- University of Virginia Cancer Center, Charlottesville
- Children's Hospital of The King's Daughters, Norfolk
被験者募集中第3相
1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Virginia Cancer Center, Charlottesville
- Inova Fairfax Hospital, Falls Church
- Children's Hospital of The King's Daughters, Norfolk
- 他2件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Children's Hospital of Richmond at Virginia Commonwealth University, Richmond
被験者募集中第3相
29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Virginia School of Medicine, Charlottesville
- Virginia Cancer Specialists, Manassas
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Virginia Comprehensive Cancer Center, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Virginia, Charlottesville
- Virginia Commonwealth University, Richmond
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
- Virginia Commonwealth University, Richmond
被験者募集中第4相
18歳以上 · 全性別 · 2026/05/29更新 · NCT06370000Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
- University of Virginia, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/11更新 · NCT07270978Cardioprotection in AML
- University of Virginia, Charlottesville
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/05更新 · NCT04977180A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- University of Virginia, Charlottesville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT05732103Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Virginia Cancer Center, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/31更新 · NCT04716452A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Virginia, Charlottesville
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
- Virginia Commonwealth University, Richmond
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/06更新 · NCT07130695ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。